Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. There are currently few available therapies to treat or prevent the consequences of kidney diseases. These diseases affect as much as 10 percent of the world's population.
The company is conducting development on two major indications; its lead program targets acute kidney injury (AKI). AKI is the sudden loss of kidney function that afflicts more than 1.2 million people each year in the United States. Patients with AKI have increased hospital stay and AKI can lead to permanent loss of kidney function. The company's second program addresses chronic kidney disease (CKD) which can also result in permanent loss of kidney function and the need for dialysis.
|02•29•16||Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI) more >|
|11•10•15||Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision more >|
|09•02•15||Thrasos to Present at the 22nd Annual BioCentury NewsMakers and 8th Annual BioPharm America Conferences more >|